KEMRI-CDC-LSTM Malaria Branch
The overall objective of the KEMRI-CDC-LSTM malaria branch is to conduct research, surveillance and capacity building in order to provide high
quality data to guide policy in Kenya, regionally and globally.
Our research focuses on; malaria case management and prevention, efficacy of vaccines and drugs, malaria in pregnancy, monitoring and evaluation of malaria control interventions, transmission reduction, surveillance, capacity building and technical support to the Kenyan National Malaria Programme (NMCP).
- Insecticide-treated bednets reduce infant mortality by 25 percent
- Intermittent Presumptive Treatment with SP reduces the burden of malaria in pregnancy
- The dosage of folic acid prescribed during pregnancy in Kenya interferes with the ability of sulfadoxine-pyrimethamine (SP) to effectively clear malaria parasites
- Intermittent preventive treatment of malaria in infants (IPTi) reduces clinical malaria in the first year of life by 25 percent
- Research aimed at developing new tools/strategies that reduce morbidity and mortality
- Surveillance to evaluate performance of current malaria control strategies
- Research aimed at developing new tools/strategies for transmission reduction
- Operational research aimed at improving uptake of known/proven malaria control strategies
|CDC IRB Number
|CDC IRB EXPIRY
|Efficacy and safety of pediatric immunization-linked preventive intermittent treatment (IPTi) with antimalarials in decreasing anemia and malaria morbidity in rural western Kenya
|Genetic Polymorphism of IL-12 p40 Subunit and MIF in Severe Malarial Anemia in Kenyan Children
|Impact of anthropegenic perturbations of the malaria anthropod vector ecology on the resiliency and stability of the malaria disease system in an holondemic region of Western Kenya
|Field workers ethics and the medical research process in western Kenya
|Investigations of factors associated with malaria and health status in orphaned street children and children living and working on the streets in Kisumu, Kenya: a cross sectional, clinic based study
|Identification of molecular markers associated with resistance to artemisinin combination therapy in kenya
|expunged from ERC agenda
|School-based distribution of insecticide-treated nets against malaria in highland areas of Western Kenya: evaluation of community level effect
|COLL M 15
|Efficacy of larviciding in reducing malaria vectors in western Kenya
|An evaluation of government health workers adherence to the national guidelines for the diagnosis and treatment of malaria in children under 5yrs of age presenting to outpatient clinics in karemo
|Artemether-lumefantrine stock outs and pattern of malaria related mortality among children under five in rural western Kenya
|deffered to KEMRI 28/11/2011
|Evaluation of the introduction of malaria control interventions on malaria parasitemia and anemia in the KEMRI/CDC HDSS.
|Chris / Megha
|COLL M 18
|Targeted application of insecticides to livestock for control of Anopheles arabiensis in western Kenya
|Cervical Cancer Screening Assessment, Kenya
|Comparison of screening strategies for identifying women eligible for Intrapartum Antibiotic Prophylaxis ……..
|CDC IRB Number
|CDC IRB EXPIRY
|Entomological evaluation of long-lasting mosquito nets in western Kenya (LLITN)
|Insecticide treated materials (Eave Curtains)
|Closed SERU letter dated 12-03-2015
|Efficacy of Dihydroartemisinin-Piperaquine and Artemether-Lumefantrine in the treatment of symptomatic, uncomplicated Plasmodium falciparum malaria among 6-59 month old children in rural western Kenya
|Entomological evaluation of long lasting mosquito nets in western kenya
|Evaluation of intermittent preventive treatment of malaria during malaria uptake (IPTp) after introduction of new guidelines by the Division of Malaria Control
|Cost effectiveness assessmentof intermittent preventive treatment of malaria i infants (IPTi) in kisumu, kenya
|INVESTIGATION OF GENE POLYMORPHISMS OF KILLER CELL IMMUNOGLOBULIN-LIKE RECEPTORS (KIRS) IN SUSCEPTIBILITY TO PLACENTAL MALARIA AND PERINATAL TRANSMISSION OF hiv-1 IN PREGNANT WOMEN IN KENYA
|Enhanced vector surveillance and insecticide resistance monitoring in western Kenya
|CLOSED ERC LETTER DATED 26FEB2013
|The Social and cultural context of malaria in pregnacy in Kenya
|Operational research to develop meytrics to monitor malaria transmission intensity through health facilities
|CLOSED ERC Letter dated 18th Nov 2014
|A pilot study of a baited trap to assess outdoor, host-feeding preferences mosquitoes and persistent feeding in anopheline mosquitoes
|CLOSED BY ERC 20/MAY2014
|Entomological evaluation of spatial repellents
|CLOSED ERC letter dated 30/06/2014
|Intermittent screening and treatment of school children against malaria in highland areas of western Kenya evaluation of school and community level effects
|Risk of malaria in persons conducting human landing catches fr monitoring of mosquito populations
|Closed ERC letter dated 28th Oct 2014
|Role of mobile phones and conditional cash transfers to improve vaccination coverage for Kenyan children in rural western Kenya
|ClOSED Letter 1st Oct 2013
|Human Papillomavirus (HPV) Vaccine Acceptability Focus Group Assessment, Kenya
|Eileen F. Dunne
|CLOSED ERC letter dated 28/2/2014
|Efficacy and Durability of the LifeNet LLIN and Royal Sentry LLIN
|ormerly SSC2194 deffered to KEMRI28/11/2011
|A Double-Blind, Controlled Trial to Evaluate the Safety, Immunogenicity, and Efficacy of Trivalent Inactivated Influenza Vaccine and Adjuvanted Trivalent Inactivated Influenza Vaccine
|CLOSED ERC letter dated 28/4/2014
ABOUT KEMRI-CDC-LSTM Malaria Branch
Malaria remains an important public health problem and an impediment to social and economic development in sub-Saharan Africa. In Kenya malaria is one of the leading causes of morbidity and mortality and 80 percent of the population is at risk. Nationally, malaria is responsible for 30 percent outpatient consultations, 19 percent hospital admissions and 3-5 percent of inpatient deaths. However, due to the heterogeneous nature of malaria distribution in the country, the burden is much higher in some areas such as western Kenya. In these areas, malaria transmission is high and perennial and is the cause of 65 percent sick visits to hospitals, 70 percent hospital admissions and 20 percent deaths.
The Kenyan Government and international partners consider investment in malaria control a high priority if the country is to achieve its long-term development plan, vision 2030. Therefore, the malaria endemic area of in western Kenya represents an ideal area to conduct research with an overall aim of reducing the high malaria burden.
Through a collaboration involving the Kenya Medical Research Institute (KEMRI), the US Centers for Disease Control and Prevention (CDC) and Liverpool School of Tropical Medicine (LSTM), we are conducting critical research studies aimed at generating data that is to malaria control progammes in formulation of evidence-based malaria prevention and control policies.
For the past 35 years, the collaboration has conducted research that informed national and international policy including; use of Sulfadoxine-Pyrimethamine (SP) as Intermittent Preventive Therapy for malaria prevention during pregnancy (IPTp), efficacy of Insecticide-Treated bednets (ITNs), documenting the increase in parasite resistance that informed the switch from chloroquine and SP to artemisinin-based combination therapies (ACTs) as first-line drugs and the use of low-dose folic acid during pregnancy.
This collaboration has led to the development of excellent Good Clinical Practice (GCP)-compliant field and laboratory infrastructure consisting of state-of-the-art laboratories with the equipment and facilities to support epidemiological studies, clinical trials and conduct basic research at satellite laboratories located at Siaya County Referral Hospital and Jaramogi Oginga Odinga Teaching and Referral Hospital, the largest hospital in western Kenya. Over the years, the collaboration has also built capacity through training and mentoring of Kenyan scientists to MSc and PhD level, resulting in a pool of well-trained multidisciplinary team of epidemiologists, clinicians, scientists, laboratory technologists, behavioral scientists and community health workers with expertise and experience in conducting large-scale population-based studies including phase 3 vaccine efficacy trials. Our scientists are members of key technical working groups (TWGs) of the Kenya’s Ministry of Health NMCP where they provide technical support in translation of research into policy and practice.